ViiV redeems voucher for fast FDA review of HIV combinationViiV Healthcare has applied for a fast US review of its single-tablet, two drug HIV drug regimen of Share XViiV redeems voucher for fast FDA review of HIV combinationhttps://pharmaphorum.com/news/viiv-redeems-voucher-for-fast-fda-review-of-hiv-combination/
MPs call for NHS funding for HIV prevention drugLeading UK politicians have called for an HIV prevention drug to be made available across the NHS, after Share XMPs call for NHS funding for HIV prevention drughttps://pharmaphorum.com/news/mps-call-for-nhs-funding-for-hiv-truvada/
Truvada ruling could allow cheap HIV prevention in the UKCheap copies of Gilead’s HIV drug Truvada, which can also be used to reduce the risk of people Share XTruvada ruling could allow cheap HIV prevention in the UKhttps://pharmaphorum.com/news/truvada-ruling-could-allow-cheap-hiv-prevention-in-the-uk/
FDA approves Merck’s Delstrigo and Pifeltro for HIV treatmentMerck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) Share XFDA approves Merck’s Delstrigo and Pifeltro for HIV treatmenthttps://pharmaphorum.com/news/fda-approves-mercks-hiv-treatment/
HIV drug cuts viral load, boosts immunity in Yale studyA Yale University study has found ibalizumab reduced viral replication and increased the count of immune cells in Share XHIV drug cuts viral load, boosts immunity in Yale studyhttps://pharmaphorum.com/news/ibalizumab-cuts-hiv-viral-load/
GSK’s monthly HIV treatment breakthroughGlaxoSmithKline has seen positive clinical results from the phase 3 study of its once-monthly injectable HIV treatment, stepping Share XGSK’s monthly HIV treatment breakthroughhttps://pharmaphorum.com/news/gsks-monthly-hiv-treatment-breakthrough/
ViiV prepares another two-drug HIV filingViiV Healthcare says it is on course to change standard care in HIV treatment by providing another combination Share XViiV prepares another two-drug HIV filinghttps://pharmaphorum.com/news/viiv-prepares-another-two-drug-hiv-filing/
FDA approves Janssen’s HIV combination SymtuzaJanssen has won US approval for its once-daily HIV pill Symtuza (D/C/F/TAF), which it hopes will improve patient Share XFDA approves Janssen’s HIV combination Symtuzahttps://pharmaphorum.com/news/fda-janssen-hiv-symtuza/
Study indicates potential breakthrough HIV drugFrench biotech Abivax might be on the verge of HIV cure and prevention discovery, after achieving a significant Share XStudy indicates potential breakthrough HIV drughttps://pharmaphorum.com/news/study-indicates-breakthrough-hiv/
